Indian-Origin Man Among First to Receive COVID-19 Vaccine in UK Rollout

On a Tuesday in early December 2020, Hari Shukla, an 87-year-old man living in Tyne and Wear in northeast England, walked into a hospital in Newcastle to receive an injection that would make him one of the first people on Earth to get a COVID-19 vaccine. The moment was deliberate, choreographed, and heavy with symbolic weight. Britain had just received regulatory approval for the Pfizer-BioNTech vaccine, and the country's health service was launching what officials were calling V-Day—the opening salvo in what would become the largest immunization campaign in NHS history.

Shukla had been selected according to criteria established by the UK's Joint Committee on Vaccination and Immunisation. People over 80, care home workers, and frontline NHS staff would go first, prioritized because they faced the highest risk of death from the virus. When the NHS notified him, Shukla accepted without hesitation. "I'm so pleased we are hopefully coming towards the end of this pandemic," he said, "and I am delighted to be doing my bit by having the vaccine. I feel it is my duty to do so and do whatever I can to help." He spoke with genuine warmth about the NHS workers he had encountered during the pandemic, calling them people with "a heart of gold."

Prime Minister Boris Johnson seized on the moment as a turning point. "Today marks a huge step forward in the UK's fight against coronavirus," he said, praising the scientists who developed the vaccine, the trial participants who tested it, and the NHS staff preparing for the rollout. But Johnson tempered the optimism with a warning: mass vaccination would take time. The country needed to remain disciplined, to keep following lockdown rules through the winter months ahead. The light at the end of the tunnel was visible, officials said, but the tunnel was still long.

The logistics were staggering. The Pfizer-BioNTech vaccine is an mRNA formula—a tiny fragment of genetic code from the virus itself, designed to teach the body how to recognize and fight COVID-19. It required two doses, spaced 21 days apart, and immunity built gradually, reaching strong protection about a week after the second shot. But the vaccine was fragile. It had to be stored at minus 70 degrees Celsius. Once thawed, it could only be moved four times within that cold chain before being administered. The NHS had spent weeks preparing for this logistical puzzle.

On V-Day itself, 50 hospital hubs across the country began vaccinating. The initial supply had arrived from Pfizer's manufacturing site in Belgium, but it was finite. NHS Chief Executive Sir Simon Stevens called the vaccine deployment "a decisive turning point in the battle with the pandemic," noting that the health service had successfully overcome tuberculosis, polio, and smallpox through vaccination programs—and now COVID-19 would be next. Health Secretary Matt Hancock urged patience. "Now's the time to sit tight and remain patient until you get notified by the NHS that it's time for your vaccination," he said.

Professor Stephen Powis, the NHS's national medical director, offered a phrase that would echo through the months ahead: the rollout would be "a marathon not a sprint." GPs and primary care staff were on standby to begin delivering doses on a phased basis. Larger vaccination centers in sports venues and conference halls would open as supply increased. The bulk of the campaign was expected to accelerate in early 2021, but there was no rushing it. The regulatory approval had been fast-tracked because the pandemic demanded urgency, but the MHRA had still conducted rigorous safety testing. Now came the harder part: vaccinating millions of people across a nation still in lockdown, still grieving, still waiting for the world to return.